IRI

Infrasense Performs a Pavement Evaluation using Ground Penetrating Radar (GPR), Falling Weight Deflectometer (FWD), and Traffic Speed Deflectometer (TSD) in New Hampshire

Retrieved on: 
Wednesday, January 10, 2024

EPPING, N.H., Jan. 10, 2024 /PRNewswire-PRWeb/ -- Infrasense recently conducted pavement structure/condition evaluations of a six-mile highway section in New Hampshire. A vehicle-based Ground Penetrating Radar (GPR) survey yielded continuous pavement layer thickness data along prescribed offsets within the project section. Falling Weight Deflectometer (FWD) testing was also performed at over 120 locations along the project section, which provided the data needed to calculate layer moduli, effective structural number (SN), remaining service life and required overlay thicknesses. Traffic Speed Deflectometer (TSD) data yielded deflection bowl measurements and was accompanied by surface distress data (rutting, cracking, IRI). The results provided the client with valuable information to facilitate rehabilitation design efforts. Deliverables included tabular and graphical datasets with each point linked to precise GPS coordinates. The GPR datasets help visualize how the constructed layers of the roadway change along the length of each lane, while the FWD and TSD datasets present remaining lift, overlay thickness, structural number, and subgrade modulus along the length of each lane.

Key Points: 
  • Infrasense recently conducted Ground Penetrating Radar (GPR) and Falling Weight Deflectometer (FWD) testing along highway NH-101.
  • EPPING, N.H., Jan. 10, 2024 /PRNewswire-PRWeb/ -- Infrasense recently conducted pavement structure/condition evaluations of a six-mile highway section in New Hampshire.
  • A vehicle-based Ground Penetrating Radar (GPR) survey yielded continuous pavement layer thickness data along prescribed offsets within the project section.
  • Traffic Speed Deflectometer (TSD) data yielded deflection bowl measurements and was accompanied by surface distress data (rutting, cracking, IRI).

Three Years of Escalating Sales Growth Forecast in US B2B Technology, Reports Circana

Retrieved on: 
Friday, January 5, 2024

Hardware sales are expected to normalize, with 3% revenue growth in 2024, followed by high single-digit gains during each of the next two years, according to the latest Future of B2B Technology Forecast from Circana , formerly IRI and The NPD Group.

Key Points: 
  • Hardware sales are expected to normalize, with 3% revenue growth in 2024, followed by high single-digit gains during each of the next two years, according to the latest Future of B2B Technology Forecast from Circana , formerly IRI and The NPD Group.
  • Year-over-year performance of software and cloud platform sales have remained positive and will lead the growth in 2024.
  • Combined B2B tech revenue growth is forecast to reach 7% by the end of 2024.
  • “The B2B technology space has finally seen the bottom of the sales losses and is primed for positive performance across all segments.”

Circana to Release New Thought Leadership at CES, Featuring Prescriptive Insights for Success in 2024

Retrieved on: 
Thursday, January 4, 2024

Chicago, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Circana ™, formerly IRI and The NPD Group, announces new thought leadership for the upcoming Consumer Electronics Show (CES), January 9 - 12, 2024, in its latest version of Next Week Now, a compilation of insights-rich activities, announcements and events.

Key Points: 
  • Chicago, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Circana ™, formerly IRI and The NPD Group, announces new thought leadership for the upcoming Consumer Electronics Show (CES), January 9 - 12, 2024, in its latest version of Next Week Now, a compilation of insights-rich activities, announcements and events.
  • The presentation will take place Monday, Jan. 8 from 2:00 – 2:40 p.m. at Las Vegas Convention Center (LVCC) West Hall, room W232.
  • Monday, Jan. 8 – Eighth Annual Consumer Technology Industry Performance Awards – Circana will announce the winners of its Eighth Annual Consumer Technology Industry Performance Awards.
  • The report features insights from Paul Gagnon and Joe Derochowski , vice president and home industry advisor at Circana.

The Simply Good Foods Company Reports Fiscal First Quarter 2024 Financial Results and Reaffirms Full Fiscal Year 2024 Net Sales and Adjusted EBITDA Outlook

Retrieved on: 
Thursday, January 4, 2024

"We are pleased with our fiscal first quarter financial results and marketplace performance that were in line with estimates," said Geoff Tanner, President and Chief Executive Officer of Simply Good Foods.

Key Points: 
  • "We are pleased with our fiscal first quarter financial results and marketplace performance that were in line with estimates," said Geoff Tanner, President and Chief Executive Officer of Simply Good Foods.
  • As a result, Adjusted EBITDA is expected to increase slightly higher than the net sales growth rate.
  • In the first quarter of fiscal 2024, total Simply Good Foods combined measured and unmeasured channel U.S. retail takeaway increased about 8%.
  • Given the good start to the year, the Company reaffirms its full year fiscal 2024 outlook.

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 3, 2024

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • With the Ministry of Health (MoH) approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey.
  • Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.

WORLD INSURANCE ASSOCIATES NAMES JOE KLEIN AS EVP OF NATIONAL ACCOUNTS

Retrieved on: 
Tuesday, January 2, 2024

Iselin, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (World), one of the fastest growing insurance brokerages in the U.S., announced today that industry leader Joe Klein will join World as an executive vice president of its national accounts practice.

Key Points: 
  • Iselin, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (World), one of the fastest growing insurance brokerages in the U.S., announced today that industry leader Joe Klein will join World as an executive vice president of its national accounts practice.
  • His expertise spans a wide range of industry sectors, including education, heavy manufacturing, energy, power, retail and aviation risks.
  • “Given the current market, insureds require more support, creativity and expertise to secure dynamic insurance programs that meet their ever-evolving needs.
  • Klein will be based out of Chicago and assumed his new role at World on January 2, 2024.

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Thursday, December 21, 2023

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The ethics committee approval of the trial will be followed by a final regulatory review conducted by the Turkish Ministry of Health (MoH), expected to be completed by mid-January.
  • Once the trial is approved by the MoH, activation of clinical sites in Turkey will take place and patient enrollment can begin in February.
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “We look forward to a positive decision from the MoH, which will permit enrollment of Turkish cardiac surgery patients into the trial.

Consumers Continue to Spend at Reduced Levels Through November Holiday Promotions, Reports Circana

Retrieved on: 
Thursday, December 14, 2023

Discretionary general merchandise spending declines continued with 7% dollar declines and a 5% decrease in unit sales compared to last November.

Key Points: 
  • Discretionary general merchandise spending declines continued with 7% dollar declines and a 5% decrease in unit sales compared to last November.
  • CPG spending gains slowed once again, with flat food and beverage revenue performance and a 1% decline in nonedible item revenue compared to last year.
  • Demand levels have also waned, with unit sales falling 2% and 5%, respectively, in edible and nonedible segments, according to Circana , formerly IRI and The NPD Group.
  • Over Black Friday Week, sales of some popular gifting categories, like portable beverageware and select toys, increased compared to last year.

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Wednesday, December 13, 2023

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The FDA granted the Company permission to proceed with a Phase II trial in late June .
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “The clinical trial application submitted to Health Canada is the result of clinical interest in Canada to support our Phase II trial targeting CS-AKI.
  • LSALT peptide has been shown to prevent ischemia reperfusion injury (IRI) to the kidneys in pre-clinical models , providing the scientific rationale for Arch to use LSALT peptide in this CS-AKI trial.

Independent Research Firm Names Circana a Strong Performer in Retail Planning Platforms

Retrieved on: 
Thursday, November 30, 2023

Chicago, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Circana™ , a leading advisor on the complexity of consumer behavior,  announced today that Forrester Research has named the company a “Strong Performer” in its “The Forrester Wave™: Retail Planning Platforms, Q4 2023” report.

Key Points: 
  • Chicago, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Circana™ , a leading advisor on the complexity of consumer behavior,  announced today that Forrester Research has named the company a “Strong Performer” in its “The Forrester Wave™: Retail Planning Platforms, Q4 2023” report.
  • Circana products and solutions evaluated by Forrester include AlwaysOn Analytics, Assortment Optimization, Gateways and Supply Chain.
  • Forrester analyzed 13 retail planning platform solutions utilizing criteria grouped into three categories: current offering, strategy and market presence.
  • Circana offers unique capabilities that enable retailers and manufacturers to drive long-term growth by identifying new opportunities for innovation, success and collaboration,” added Wei Lin Wong, president, Global Retail, Circana.